Screener
Amneal Pharmaceuticals, Inc. AMRX Oral solid — Net revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Affordable Medicines | ||||
| Oral solid | $175,172 | $178,262 | $346,272 | $357,215 |
| Transdermal | 67,038 | 40,710 | 141,001 | 83,773 |
| Auto-Injector | 62,214 | 66,594 | 104,126 | 114,754 |
| Injectable | 56,783 | 34,646 | 106,721 | 69,434 |
| Biosimilar | 29,128 | 25,248 | 51,429 | 53,788 |
| Oral liquid | 10,371 | 17,879 | 22,463 | 41,427 |
| Other dosage forms (1) | 81,594 | 68,185 | 128,206 | 124,607 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s oral solid — net revenue?
- Amneal Pharmaceuticals, Inc. (AMRX) reported oral solid — net revenue of $175.17M in Q2 2026.
- How has Amneal Pharmaceuticals, Inc.'s oral solid — net revenue changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s oral solid — net revenue decreased by 1.7% year-over-year, from $178.26M to $175.17M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s oral solid — net revenue?
- Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s oral solid — net revenue has grown at a 3.6% compound annual growth rate (CAGR), from $652.74M to $726.38M.
- What does oral solid — net revenue mean?
- This metric represents the total net sales generated from the sale of oral solid dosage pharmaceutical products, such as tablets and capsules, after accounting for returns, rebates, and allowances. It serves as a primary indicator of the commercial performance and market demand for the company's core generic and specialty oral medication portfolio. Monitoring this revenue stream helps investors assess the stability and growth trajectory of the company's most traditional and high-volume product delivery segment.
Ask your AI about Amneal Pharmaceuticals, Inc.'s oral solid — net revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude